Cargando…

Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients

AIMS: There is increasing evidence that plasma biomarkers are specific biomarkers for Alzheimer's disease (AD) pathology, but their potential utility in Obj‐SCD (objectively defined subtle cognitive decline) remains unclear. METHODS: A total of 234 subjects, including 65 with brain amyloid beta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Yanlu, Li, Yuehua, Xie, Fang, Guo, Qihao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627371/ https://www.ncbi.nlm.nih.gov/pubmed/36074638 http://dx.doi.org/10.1111/cns.13962

Ejemplares similares

Objective subtle cognitive decline and plasma phosphorylated tau181: Early markers of Alzheimer's disease‐related declines
por: Thomas, Kelsey R., et al.
Publicado: (2021)

Local Functional MR Change Pattern and Its Association With Cognitive Function in Objectively-Defined Subtle Cognitive Decline
por: Cui, Liang, et al.
Publicado: (2021)

Plasma phosphorylated tau181 predicts cognitive and functional decline
por: Tropea, Thomas F., et al.
Publicado: (2022)

Tau levels are higher in objective subtle cognitive decline but not subjective memory complaint
por: Thomas, Kelsey R., et al.
Publicado: (2022)

Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients
por: Traub, Jan, et al.
Publicado: (2022)

Plasma p-tau181, neurofilament light chain and association with cognition in Parkinson’s disease
por: Batzu, Lucia, et al.
Publicado: (2022)

Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals
por: Lussier, Firoza Z, et al.
Publicado: (2021)

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease
por: Moscoso, Alexis, et al.
Publicado: (2021)

Reference intervals for plasma amyloid-β, total tau, and phosphorylated tau181 in healthy elderly Chinese individuals without cognitive impairment
por: Chen, Jingshan, et al.
Publicado: (2023)

Altered functional connectivity pattern of hippocampal subfields in individuals with objectively‐defined subtle cognitive decline and its association with cognition and cerebrospinal fluid biomarkers
por: Qiu, Tiantian, et al.
Publicado: (2022)

Estimation of Tau and Phosphorylated Tau(181) in Serum of Alzheimer’s Disease and Mild Cognitive Impairment Patients
por: Shekhar, Shashank, et al.
Publicado: (2016)

Plasma amyloid beta 40/42, phosphorylated tau 181, and neurofilament light are associated with cognitive impairment and neuropathological changes among World Trade Center responders: A prospective cohort study of exposures and cognitive aging at midlife
por: Kritikos, Minos, et al.
Publicado: (2023)

Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression
por: Clark, Christopher, et al.
Publicado: (2021)

Subtle executive deficits are associated with higher brain amyloid burden and lower cortical volume in subjective cognitive decline: the FACEHBI cohort
por: Pérez-Cordón, Alba, et al.
Publicado: (2020)

Correlation between cognitive impairment and serum phosphorylated tau181 protein in patients with preeclampsia
por: Wang, Yuanyuan, et al.
Publicado: (2023)

Amyloid duration is associated with preclinical cognitive decline and tau PET
por: Koscik, Rebecca L., et al.
Publicado: (2020)

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status
por: Shen, Xue-Ning, et al.
Publicado: (2021)

Differential associations of visual memory with hippocampal subfields in subjective cognitive decline and amnestic mild cognitive impairment
por: Huang, Yanlu, et al.
Publicado: (2022)

Cognitive Heterogeneity and Risk of Progression in Data-Driven Subtle Cognitive Decline Phenotypes
por: Thomas, Kelsey R., et al.
Publicado: (2022)

Altered metamemory precedes cognitive impairment in subjective cognitive decline with positive amyloid-beta
por: Li, QinJie, et al.
Publicado: (2022)

Correlation between ankle‐brachial index and subtle cognitive decline
por: Guo, Hui‐Feng, et al.
Publicado: (2023)

Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline
por: Ossenkoppele, Rik, et al.
Publicado: (2022)

Plasma Phosphorylated-tau181 Is a Predictor of Post-stroke Cognitive Impairment: A Longitudinal Study
por: Huang, Li-Kai, et al.
Publicado: (2022)

Oh brother, where art tau? Amyloid, neurodegeneration, and cognitive decline without elevated tau
por: McCollum, Lauren E., et al.
Publicado: (2021)

Meaningful cognitive decline is uncommon in virally suppressed HIV, but sustained impairment, subtle decline and abnormal cognitive aging are not
por: Aung, Htein Linn, et al.
Publicado: (2022)

Sex differences in plasma p-tau181 associations with Alzheimer’s disease biomarkers, cognitive decline, and clinical progression
por: Tsiknia, Amaryllis A., et al.
Publicado: (2022)

White matter hyperintensity, neurofilament light chain, and cognitive decline
por: Dhana, Anisa, et al.
Publicado: (2022)

Microglial activation and tau burden predict cognitive decline in Alzheimer’s disease
por: Malpetti, Maura, et al.
Publicado: (2020)

Amyloid- β and tau deposition influences cognitive and functional decline in Down syndrome
por: Grigorova, Monika, et al.
Publicado: (2022)

Amyloid-β levels and cognitive trajectories in non-demented pTau181-positive subjects without amyloidopathy
por: Oberstein, Timo Jan, et al.
Publicado: (2022)

Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function
por: Lehmann, Sylvain, et al.
Publicado: (2023)

A comparative study on the validations of three cognitive screening tests in identifying subtle cognitive decline
por: Pan, Feng-Feng, et al.
Publicado: (2020)

Network interdigitations of Tau and amyloid‐beta deposits define cognitive levels in aging
por: Kim, Chan‐Mi, et al.
Publicado: (2021)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Olfactory identification in subjective cognitive decline and mild cognitive impairment: Association with tau but not amyloid positron emission tomography
por: Risacher, Shannon L., et al.
Publicado: (2017)

Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age
por: Betthauser, Tobey J, et al.
Publicado: (2020)

Circulating Neurofilament Light Predicts Cognitive Decline in Patients With Post-stroke Subjective Cognitive Impairment
por: Wang, Jian-Hong, et al.
Publicado: (2021)

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease
por: Pichet Binette, Alexa, et al.
Publicado: (2022)

Rosmarinic acid suppresses tau phosphorylation and cognitive decline by downregulating the JNK signaling pathway
por: Yamamoto, So, et al.
Publicado: (2021)

Hippocampal and Amygdala Gray Matter Loss in Elderly Controls with Subtle Cognitive Decline
por: Zanchi, Davide, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_3lqdl38s4qrfn8vfq09p5kef3u